Novel sequential treatment with palbociclib enhances the effect of cisplatin in RB-proficient triple-negative breast cancer

Novel sequential treatment with palbociclib enhances the effect of cisplatin in RB-proficient triple-negative breast cancer

Abstract Background Triple-negative breast cancer (TNBC) is a highly aggressive malignancy that lacks sensitivity to chemotherapy, endocrine therapy or targeted therapy. CDK4/6 inhibitors, combined with endocrine therapy, have been shown to be effective in postmenopausal women with HR-positive, HER2...

Full description

Bibliographic Details
Main Authors: Yajing Huang, Hao Wu, Xingrui Li
Format: Article
Language:English
Published: BMC 2020-10-01
Series:Cancer Cell International
Subjects:
Palbociclib
Cisplatin
RB
Cell cycle
Triple-negative breast cancer
Online Access:http://link.springer.com/article/10.1186/s12935-020-01597-x

Internet

http://link.springer.com/article/10.1186/s12935-020-01597-x

Similar Items